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I~  Determination of an immunoreactive trypsinogen (IRT) cut-off 
value for a neonatal CF screening program 
M.D. Montgomery 1,4, S. Menon 1, L. Semple 1 , D. Forrest 2, P.J. Bridge 2,3,5, H.M. Wilde 1 , 
C.L. Larsen 1, M.E. Lyon 5,6,7. 1Cystic Fibrosis Clinic, 2Molecular Diagnostics Laboratory, 
Alberta Children ~ Hospital, 3Medical Genetics, 4pediatrics, 5pathology cad Laboratory Medicine, 
6Pharmacology cad Therapeutics, University of Calgary, 7 Calgary Laboratory Services, Calgary, AB, 
Canada 
Aim: To deterlnine an IRT cut-off value tl~at will detect all CF patients while minimizing fire number 
of CF carriers identified. 
Methods and Results: Two 3 mrn dried blood spots obtained from newborn screening cards were 
ai/alyzed for fire imnmnoreactive trypsinogen (IRT) concentration using the enzyme immunoassay 
Quantase Neoi/atal IRT Screening Assay ® (Bio-Rad Laboratories, Europe Ltd, Perth, Scotland, UK) 
followed by testing for 44 CFTR mutations u ing fire Tag-It TM Mutation Detection Kit CFTR 40+4 ® 
(Tin Bioscience Corporation, Toronto, Canada). The results for fire first 800 individuals from a sample 
size of 2000 are included (table). 
Distribution of carriers by IRT concentration 
[IRT] range % of samples Mutations detected Carrier Mutations 
(~tg/L) in IRT range Two One frequency 
12. Screening 
l~How stable is immunoreactive trypsinogen (IRT) on newborn 
screening cards? 
C.L. Larsen i , S. Menon i , L. Semple i , RJ. Bridge 2'3'5, M.D. Montgomery i '4, 
M.E. Lyon 5'6'7. 1 Cystic Fibrosis' Clinic, 2Molecular Diagnostics' Laboratory, 
Alberta Children ~' Hospital, 3Medical Genetics', 4pediatrics, 5pathology and 
Laboratory Medicine, 6pharmacology and Therapeutics, University of Calgary, 
7Calgary Laboratory Services', Calgary, AB, Canada 
Aim: The overall goal of this study was to determine the time course of IRT stability 
when newborn screening cards were stored at 20°C, 4°C or 22°C. 
Methods:  EDTA anti-coagulated cord blood specimens were applied to newborn 
screening cards (n 12 for each temperature). These cards were stored at three 
different emperatures ( 20°C, 4°C or 22°C) and analyzed at various time points up 
to 6 months. The concentration of IRT was measured using the BioRad ® Quantase 
immunoassay according to the manufacturer's specifications. 
Results: see the table. 
Concentration of IRT (gg/L)(mean±2SD) 
0 19 65.6% 10 2% 6dF508, 21148T, 1 1717 1G>A, 1 3659delC 
20 39 22.7% 3 2% 2 dF508, 1 I48T 
40 59 6.8% 1 2% 1 dF508 
60 79 2.4% 3 16% 2 dF508, lRl17H 
80 99 1.0% 0 0% 
100 119 1.0% 0 0% 
120 139 0.3% 1' 0 0% 1 dF508/Rl17H 
140 159 0.0% 0 0% 
160 179 0.0% 0 0% 
180 199 0.0% 1' 0 0% 1 dF508/dF508 
*CF individuals with 2 mutations detected i entified tfirough tile screening program, but not part of 
tile sample of 2000, included for comparison purposes 
Conclusions: (1) CF affected individuals /ave significantly elevated IRT concentrations relative to 
CF carriers. (2) An inverse relationship exists between tile nuinber of CF carriers identified and 
IRT cut-off values. (3) Tile type of CF nmtation does not appear to influence tile concentration f 
IRT in CF carriers. 
0 hr 24 hr 1 week 2 weeks 3 weeks 4 weeks 6 months 
20°C 39±26 32±16 28±14 36±32 31±22 41±14 46±12 
4°C 39±26 30±16 27±10 32±15 28±14 38±16 44±16 
22°C 39±26 34±16 35±12 32±19 42±14 40±20 35±18 
A regression analysis was conducted resulting in slope values not significantly 
different from zero. This indicates minimal variability in the data. 
Conclus ion:  The temperature at which newborn screening cards are stored has a 
negligible impact on the concentration of  IRT for up to 6 months. 
I• Newborn cystic fibrosis (CF) screening in Canada: Our first 
experience 
M.D. Montgomery 1,4, S. Menon 1, L. Semple 1, L. Gillis 1, M. Stephenson 1, 
I. Mitchell 1,4, RJ. Bridge 2,3,5, C.L. Larsen 1, M.E. Lyon 5,6,7. 1Cystic Fibrosis Clinic, 
2Molecular Diagnostics Laboratory, Alberta Children's Hospital, 3Medical Genetics, 
4pediatrics, 5Pathology arid Laboratory Medicine, 6Pharmacology arid Therapeutics, 
University of Calgary, 7Calgary Laboratory Services, Calgary; AB, Canada 
Aims: To establish a pilot project in the Calgary Health Region to screen newborns at 
risk for CE 
Methods: Newborn screening for CF was initiated June 1,2005. A total of 8556 infants 
have been screened. Two 3 mm dried blood spots obtained from newborn screening 
cards were analyzed for elevated immunoreactive trypsinogen (IRT) concentrations 
using the enzyme immunoassay Quantase Neonatal IRT Screening Assay ® (Bio-Rad 
Laboratories, Europe Ltd, Perth, Scotland, UK) followed by testing for 44 CFTR 
mutations using the Tag-It TM Mutation Detection Kit CFTR 40+4 ® (Tin Bioscience 
Corporation, Toronto, Canada). Mutation analysis was performed on the top 8% of IRT 
specimens. All infants with one or two CF mutations detected or an IRT in the highest 
0.1% were recalled for pilocarpine iontophoresis. One case of CF was confirmed in a 
child positive for two dF508 mutations. The first 6 months of testing is reported. 
Results: see the table. 
6 Month Screening Summary 
The highest % of [IRT] # of samples Two mutations One mutation Carrier 
I RT values (~tg/L) detected detected Frequency 
0.1 159 9 1 2 22% 
1 98 86 2 6 7% 
2 76 172 2 15 9% 
4 59 343 2 25 7% 
8 47 645 2 42 7% 
One infant with an elevated IRT but with no detected CF mutations was not recalled. 
A CF diagnosis was made based on clinical presentation. 
Conclusions: We were successful in the identification and recall of newborns consid- 
ered at risk for CE Currently, we are establishing an IRT cut-off value to identify CF 
affected individuals and minimize the number of non-affected CF carriers recalled. 
1• Newborn cystic fibrosis (CF) screening in Canada: considerations 
regarding the selection of a molecular genetic assay 
RJ. Bridge 1'3'5, D.N. Forrest 1, J.S. Parboosingh 1'3, S. Menon 2, L. Semple 2, 
H.M. Wilde 2, C.L. Larsen 2, F.R Bernier 3, M.E. Lyon 5'6'7, M.D. Montgomery 2'4. 
1Molecular Diagnostic Laboratory, 2Cystic Fibrosis Clinic, Alberta Children~' 
Hospital, 3Medical Genetics', 4pediatrics, 5pathology and Laboratory Medicine, 
6pharmacology and Therapeutics', University of Calgary, 7Calgary Laboratory 
Services', Calgary, AB, Canada 
Aim: To choose the optimal mutation assay platform for a newborn CF screening 
program. 
Methods:  Since 1997 we have used the CF mutation kit from Applied Biosystems 
(ABI, later Roche and/or Celera) with a capillary electrophoresis instrument. Two 
groups of individuals had mutations undetectable by this assay: (1) Hutterites with 
the Ml101K mutation; (2) those with clinical CF but undetectable mutations. 
Hutterites had a specific test for Ml101K (by sequence analysis). A Toronto 
research laboratory provided full gene sequencing for individuals with undetectable 
mutations. We aimed to establish a single high-throughput assay used dried blood 
samples that would detect all mutations identified previously in Alberta. 
Results: Tm Bioscience Corporation (Toronto, Canada) provided a customized kit 
that detected all standard CF mutations, the Hutterite M1101K mutation, plus all 
rare or unique mutations previously identified in our population. The Tag-It TM assay 
uses a universal bead array platform to detect specific alleles. Since the kit does 
not use all of  the available beads, it was straightforward for the company to include 
additional mutations pecified by us. 
Conclus ion:  The Tag-It TM assay has proven to provide high-throughput analysis 
of newborn dried blood specimens for our CF screening program. Using this 
customized kit including all mutations previously found in our population, the 
detection rate is expected to be close to 100%. 
